Complement C5 inhibition in patients with COVID-19 - a promising target?

Haematologica. 2020 Dec 1;105(12):2847-2850. doi: 10.3324/haematol.2020.260117.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • COVID-19 / immunology
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • Complement C5 / antagonists & inhibitors*
  • Complement Inactivating Agents / therapeutic use*
  • Humans
  • Prognosis
  • SARS-CoV-2 / drug effects*
  • SARS-CoV-2 / immunology

Substances

  • Antibodies, Monoclonal, Humanized
  • Complement C5
  • Complement Inactivating Agents
  • eculizumab